Is Family Care overvalued or undervalued?

As of 23 October 2025, the valuation grade for Family Care has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 0.80, an EV to EBITDA ratio of 0.96, and a remarkable ROE of 219.63%. In comparison to its peers, Max Healthcare is very expensive with a PE ratio of 97.78, while Apollo Hospitals is fairly valued at a PE of 72.91, indicating that Family Care is significantly undervalued relative to these competitors.
Despite the fair valuation, Family Care's stock has underperformed compared to the Sensex, with a year-to-date return of -34.23% versus the Sensex's 8.21%. This underperformance highlights potential market concerns, but the strong financial ratios suggest that Family Care may present a buying opportunity for investors looking for value in the healthcare services sector.